Seven attorneys from global law firm Greenberg Traurig, LLP are recognized in the 2022 edition of the Intellectual Asset Management (IAM) Strategy 300: The World’s Leading Intellectual Property (IP) Strategists.
According to the publication, the IAM Strategy 300 identifies leading individuals in the implementation and development of strategies that maximize the value of IP portfolios. Those recognized can only qualify for IAM Strategy 300 if they were nominated by at least three people from outside of their organization. Only individuals proven to have exceptional skill sets and profound insights into the creation, development, and management of IP value are featured in the publication.
The following shareholders were selected:
- James J. DeCarlo is actively involved in virtually all aspects of IP counseling and focuses on litigating, licensing, and procuring patents in the software, hardware, internet, and networking spaces, among many others.
- David J. Dykeman, co-chair of the firm's global Life Sciences & Medical Technology Group, focuses on securing worldwide IP protection and related business strategy for high-tech clients, with particular experience in life sciences, medical devices, robotics, materials, and information technology.
- Roman Fayerberg is a registered patent attorney who works with clients to develop and manage worldwide patent portfolios and counsels clients in regard to freedom to operate, patent landscape, and patent infringement and validity matters.
- Chinh H. Pham, co-chair of the Venture Capital & Emerging Technology Practice, is a registered patent attorney focusing on the strategic creation, implementation, and protection of IP rights for high technology and life science clients ranging from startups to multinational corporations.
- Barry J. Schindler, co-chair of the Global Patent Prosecution Group, represents numerous major companies and startups regarding patents and trade secrets and managing their worldwide patent portfolio in technical areas of AgriTech, FoodTech, Fintech, cloud computing, chemical, pharmaceutical, material science, and medical devices.
- Andrew B. Schwaab focuses on strategic IP matters, including counseling, global patent portfolio management, patent litigation, licensing, SEP/FRAND, monetization, and due diligence, as well as validity, infringement, and freedom-to-operate issues.
- Fang Xie, Ph.D. focuses her practice on establishing, defending, licensing, sharing, and monetizing IP rights for life sciences companies.
Original source can be found here.